

## Special Issue

# Predictive Biomarkers for Colorectal Cancer

### Message from the Guest Editor

An ideal biomarker can help provide optimal treatment by predicting the efficacy and safety of chemotherapeutic treatments, including biologics and immune checkpoint inhibitors. Although many biomarker studies have been reported to date, few validated markers have been identified. In recent years, genetic testing for *RAS*, *BRAF*, and MSI has led to the development of individualized treatment for colorectal cancer, and research using new diagnostic techniques is actively being conducted worldwide. This Special Issue includes RNA and miRNA expression analysis, determination of methylation status, DNA and RNA sequencing, RNA quantification, SNP genotyping, genetic analysis of circulating tumor DNA, and analysis of plasma cytokine levels. Finally, we aim to highlight potential predictive markers for colorectal cancer patients receiving anticancer therapy.

---

### Guest Editor

Dr. Mitsukuni Suenaga

Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (TMDU), 1-5-45 Yushima, Bunkyo-Ku, Tokyo 113-8510, Japan

---

### Deadline for manuscript submissions

closed (21 March 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/176917](https://mdpi.com/si/176917)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)